Need a ride to the moon? Two Houston companies are working on developing lunar rideshare services. Photo via intuitivemachines.com

Houston-based space exploration company Intuitive Machines soon will be the Uber of space.

Intuitive Machines has signed a deal with Houston-based launch services company SEOPS to offer lunar rideshare services. Under the deal, Intuitive Machines will enable SEOPS to deliver customers' payloads to the surface of the moon, as well as to Lagrange points and geostationary transfer orbits. Essentially, this will let SEOPS hitch a ride on missions already planned by Intuitive Machines.

As NASA explains, spacecraft occupy Lagrange points between the earth and moon as “parking lots” so they can stay in a fixed position while conserving fuel. And according to the European Space Agency, transfer orbits “are a special kind of orbit used to get from one orbit to another.”

“Intuitive Machines’ rideshare capacity not only satisfies a growing market need, but it’s completely in our wheelhouse — leveraging our expertise in solving complex launch challenges for our customers,” Chad Brinkley, CEO of SEOPS, says in a news release. “It makes financial sense to take advantage of the excess capacity on Intuitive Machines’ lunar missions, while also supporting our customers' goals for lunar exploration.”

Intuitive Machines CEO Steve Altemus says the SEOPS deal underscores the aspirations of the space industry.

“SEOPS entrusting us with the delivery of its customers’ payloads to space highlights our capabilities to provide the essential infrastructure and services that support all groundbreaking commercial ambitions in space,” Altemus says.

Speaking of groundbreaking developments, Intuitive Machines recently pinned down a landing site for its sold-out mission to the South Pole. The mission will prospect for water ice.

NASA calls water ice “a valuable resource” for exploration of the moon, as it could provide drinking water, cool equipment, and generate fuel and oxygen.

The more than 650-foot-in-diameter South Pole landing site, chosen by Intuitive Machines and NASA, sits on the Shackleton connecting ridge. The ridge connects two craters.

NASA says the Shackleton ridge receives enough sunlight to power a lander for a roughly 10-day mission while offering a clear line of sight for satellite communications.

The mission, featuring an Intuitive Machines lander and NASA ice-mining equipment, is set for late 2024. The work must take place between November 2024 and January 2025 to capitalize on ideal conditions.

“A sold-out commercial and civil government mission early in our commercialization roadmap validates our approach to supporting an economy in deep space,” Altemus says in a news release. “Our expertise in landing site selection is world-class, and we believe the ability to identify landing areas with valuable resources will be essential to the future of the lunar economy.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”